IUHEALTHARNETT IS AMONG THE FIRST IN INDIANA TO OFFER HYBRID CLOSED LOOP TECHNOLOGY
An IU Health Arnett Hospital Release
—Indiana University Health Arnett is one of three health care providers in Indiana testing a hybrid closed loop system with 8 patients. On September 28, 2016 – the FDA approved the first hybrid closed-loop system for automating insulin delivery to reduce both highs and lows.
A local type 1 diabetes patient is among the first in the country to receive Medtronic’s MiniMed 670G system as part of a Customer Training Phase. Referred to by some as an “artificial pancreas,” this smart insulin pump automates and personalizes basal insulin delivery 24 hours a day – stabilizing blood sugar levels with less patient interaction required. It is the first and only FDA-approved pump that tailors treatment with a smart algorithm that learns the unique needs of each patient.
“This technology is a significant breakthrough for patients with type 1 diabetes as it will take on more of the work for patients and alleviate some of the mental burden associated with daily management,” said Shannon Oates, MD, FACE, specialist in endocrinology. “I’m confident this therapy will improve patient outcomes as demonstrated by the pivotal trial that studied the device, and enhance quality of life. We’re proud to be one of the first in the nation to be able to offer it.”
The hybrid closed loop is a system that constantly self-adjusts to automatically keep your sugar levels in range, based on how you live your everyday life. This provides a peace of mind in knowing a person will be in normal blood sugar range a great majority of the time.
We now have a good idea of what to expect from hybrid closed-loop systems that automate insulin delivery:
Waking up most mornings with an on-target blood sugar (e.g., 120 mg/dl).
More time-in-range and less time spent at extreme high and low blood sugars throughout the day and especially at night.
Improvements in A1C for some users with less glucose variability (up-and-down swings).
Less diabetes hassle and greater peace of mind for many users, particularly overnight and especially for parents.
Improved sleep quality in many users.
More important, these devices may also save lives. One of the big untold stories in diabetes is death from hypoglycemia overnight (so-called “dead in bed”). There are no statistics on how often “dead in bed” happens. “Dead in bed” should never happen. With the right technology and access, people with diabetes should never have to visit the ER due to severe hypoglycemia or DKA. All these events are avoidable with the right management and access to the right technology.
Type 1 diabetes is an autoimmune disease that results when the pancreas stops making insulin. Of those who live with diabetes, about 5% have type 1 diabetes. The prevalence of diabetes is growing and today approximately 1.25 million American children and adults have type 1 diabetes.